Mark J Smyth

List of Publications by Year
in descending order

649 papers	98,212 citations	177 153 h-index	333 286 g-index
731 all docs	731 docs citations	731 times ranked	76855 citing authors

#	Article	IF	Citations
1	Cancer Immunoediting: Integrating Immunityâ€™s Roles in Cancer Suppression and Promotion. Science, 2011, 331, 1565-1570.	6.0	4,987
2	Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 2011, 29, 235-271.	9.5	1,691
3	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1Î²â€"dependent adaptive immunity against tumors. Nature Medicine, 2009, 15, 1170-1178.	15.2	1,614
4	Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450, 903-907.	13.7	1,204
5	Immune surveillance of tumors. Journal of Clinical Investigation, 2007, 117, 1137-1146.	3.9	1,198
6	Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research, 2015, 75, 2139-2145.	0.4	1,167
7	New insights into cancer immunoediting and its three component phasesâ€"elimination, equilibrium and escape. Current Opinion in Immunology, 2014, 27, 16-25.	2.4	1,163
8	NKT cells: what's in a name?. Nature Reviews Immunology, 2004, 4, 231-237.	10.6	1,097
9	Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167.	12.5	1,093
10	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482, 400-404.	13.7	1,075
11	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of Oncology, 2014, 25, 1544-1550.	0.6	1,022
12	Functional significance of the perforin/granzyme cell death pathway. Nature Reviews Immunology, 2002, 2, 735-747.	10.6	994
13	Translational biology of osteosarcoma. Nature Reviews Cancer, 2014, 14, 722-735.	12.8	939
14	Type I interferons in anticancer immunity. Nature Reviews Immunology, 2015, 15, 405-414.	10.6	929
15	Targeting natural killer cells in cancer immunotherapy. Nature Immunology, 2016, 17, 1025-1036.	7.0	865
16	Cancer cellâ€"autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	15.2	823
17	The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer, 2008, 8, 782-798.	12.8	788
18	NKT cells: facts, functions and fallacies. Trends in Immunology, 2000, 21, 573-583.	7.5	771

#	Article	IF	Citations
19	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	12.5	753
20	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 2013, 39, 74-88.	6.6	739
21	Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells. Journal of Experimental Medicine, 2000, 191, 661-668.	4.2	720
22	Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Medicine, 2001, 7, 94-100.	15.2	700
23	Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. Advances in Immunology, 2006, 90, 1-50.	1.1	689
24	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	2.1	686
25	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241.	12.5	679
26	IL-21 regulates germinal center B cell differentiation and proliferation through a B cellâ€“intrinsic mechanism. Journal of Experimental Medicine, 2010, 207, 365-378.	4.2	661
27	IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. Journal of Experimental Medicine, 2010, 207, 353-363.	4.2	659
28	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nature Medicine, 2015, 21, 719-729.	15.2	658
29	New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer, 2002, 2, 850-861.	12.8	655
30	A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology, 2001, 2, 293-299.	7.0	650
31	CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity. Journal of Immunology, 2006, 176, 1517-1524.	0.4	650
32	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
33	Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical Cancer Research, 2013, 19, 5636-5646.	3.2	598
34	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 2016, 6, 1382-1399.	7.7	592
35	Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice. Journal of Immunology, 2002, 168, 1356-1361.	0.4	582
36	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. Immunity, 2013, 38, 729-741.	6.6	572

#	Article	IF	Citations
37	Activation of NK cell cytotoxicity. Molecular Immunology, 2005, 42, 501-510.	1.0	560
38	Control of Metastasis by NK Cells. Cancer Cell, 2017, 32, 135-154.	7.7	549
39	Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer, 2017, 17, 709-724.	12.8	526
40	Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2010, 24, 22-32.	3.3	505
41	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nature Immunology, 2017, 18, 1004-1015.	7.0	504
42	Perforin-mediated target-cell death and immune homeostasis. Nature Reviews Immunology, 2006, 6, 940-952.	10.6	494
43	Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nature Reviews Immunology, 2005, 5, 112-124.	10.6	493
44	Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1547-1552.	3.3	492
45	Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010, 29, 5346-5358.	2.6	489
46	Anti-TIM3 Antibody Promotes T Cell IFN-Î³â€“Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Research, 2011, 71, 3540-3551.	0.4	489
47	Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon Î³â€“Dependent Natural Killer Cell Protection from Tumor Metastasis. Journal of Experimental Medicine, 2001, 193, 661-670.	4.2	484
48	Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma. Journal of Experimental Medicine, 2000, 192, 755-760.	4.2	481
49	Perforin and interferon-Î³ activities independently control tumor initiation, growth, and metastasis. Blood, 2001, 97, 192-197.	0.6	478
50	TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062.	3.9	470
51	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10833-10838.	3.3	468
52	TGF-Î² inhibits the activation and functions of NK cells by repressing the mTOR pathway. Science Signaling, 2016, 9, ra19.	1.6	453
53	Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 2017, 52, 71-81.	3.4	437
54	Activating and inhibitory receptors of natural killer cells. Immunology and Cell Biology, 2011, 89, 216-224.	1.0	426

#	Article	IF	Citations
55	Antiâ€“ErbB-2 mAb therapy requires type I and II interferons and synergizes with antiâ€“PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7142-7147.	3.3	413
56	Diverse cytokine production by NKT cell subsets and identification of an IL-17â€“producing CD4 ^{âˆ’} NK1.1 ^{âˆ’} NKT cell population. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11287-11292.	3.3	410
57	The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nature Immunology, 2014, 15, 431-438.	7.0	410
58	Balancing natural killer cell activation through paired receptors. Nature Reviews Immunology, 2015, 15, 243-254.	10.6	410
59	Critical Role for Tumor Necrosis Factorâ€“related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development. Journal of Experimental Medicine, 2002, 195, 161-169.	4.2	407
60	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 2012, 18, 1224-1231.	15.2	406
61	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11091-11096.	3.3	406
62	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
63	Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Research, 2013, 19, 5626-5635.	3.2	381
64	Granzymes: exogenous porteinases that induce target cell apoptosis. Trends in Immunology, 1995, 16, 202-206.	7.5	369
65	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	6.0	367
66	NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International Immunology, 2001, 13, 459-463.	1.8	365
67	The pre-metastatic niche: finding common ground. Cancer and Metastasis Reviews, 2013, 32, 449-464.	2.7	364
68	Sequential production of interferon-Î³ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of Î±-galactosylceramide. Blood, 2002, 99, 1259-1266.	0.6	362
69	CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer. Journal of Immunology, 2006, 176, 1582-1587.	0.4	362
70	Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 2013, 21, 2122-2129.	3.7	361
71	CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis. Cancer Research, 2011, 71, 2892-2900.	0.4	353
72	Acquired resistance to immunotherapy and future challenges. Nature Reviews Cancer, 2016, 16, 121-126.	12.8	353

#	Article	IF	Citations
73	<scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 2017, 276, 112-120.	2.8	351
74	Differential antitumor immunity mediated by NKT cell subsets in vivo. Journal of Experimental Medicine, 2005, 202, 1279-1288.	4.2	349
75	Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature, 2009, 461, 659-663.	13.7	348
76	Cytokines in cancer immunity and immunotherapy. Immunological Reviews, 2004, 202, 275-293.	2.8	346
77	IL-21 Is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production. Journal of Immunology, 2007, 178, 2827-2834.	0.4	338
78	A Natural Killer T (NKT) Cell Developmental Pathway Involving a Thymus-dependent NK1.1âˆ'CD4+ CD1d-dependent Precursor Stage. Journal of Experimental Medicine, 2002, 195, 835-844.	4.2	332
79	BAFF and MyD88 signals promote a lupuslike disease independent of T cells. Journal of Experimental Medicine, 2007, 204, 1959-1971.	4.2	332
80	Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon Î³. Journal of Experimental Medicine, 2002, 196, 129-134.	4.2	329
81	The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7024-7029.	3.3	328
82	Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunology, 2003, 4, 175-181.	7.0	327
83	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. Lancet Oncology, The, 2019, 20, 371-382.	5.1	327
84	Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity. Cancer Research, 2010, 70, 855-858.	0.4	326
85	Nature's TRAILâ€"On a Path to Cancer Immunotherapy. Immunity, 2003, 18, 1-6.	6.6	324
86	Presumed guilty: natural killer T cell defects and human disease. Nature Reviews Immunology, 2011, 11, 131-142.	10.6	324
87	A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas. Journal of Experimental Medicine, 2002, 196, 119-127.	4.2	322
88	Induction of tumor-specific T cell memory by NK cellâ€“mediated tumor rejection. Nature Immunology, 2002, 3, 83-90.	7.0	319
89	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	2.2	317
90	NKG2D function protects the host from tumor initiation. Journal of Experimental Medicine, 2005, 202, 583-588.	4.2	316

#	Article	IF	Citations
91	Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche. Cancer Research, 2012, 72, 3906-3911.	0.4	316
92	CD73: a potent suppressor of antitumor immune responses. Trends in Immunology, 2012, 33, 231-237.	2.9	310
93	Blockade of A _{2A} receptors potently suppresses the metastasis of CD73 ⁺ tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14711-14716.	3.3	306
94	Contribution of IL-17â€"producing Î³Î´ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 491-503.	4.2	303
95	DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. Journal of Experimental Medicine, 2008, 205, 2965-2973.	4.2	302
96	Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Research, 2011, 71, 4809-4820.	0.4	302
97	Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends in Biochemical Sciences, 2000, 25, 1-6.	3.7	301
98	Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer Cell, 2016, 30, 391-403.	7.7	300
99	IL-21 Induces the Functional Maturation of Murine NK Cells. Journal of Immunology, 2004, 172, 2048-2058.	0.4	294
100	CIS is a potent checkpoint in NK cellâ€"mediated tumor immunity. Nature Immunology, 2016, 17, 816-824.	7.0	289
101	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood, 1999, 93, 1075-1085.	0.6	288
102	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Journal of Experimental Medicine, 2012, 209, 1869-1882.	4.2	281
103	The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent. Journal of Immunology, 2000, 165, 2665-2670.	0.4	273
104	Glycolipid Antigen Drives Rapid Expansion and Sustained Cytokine Production by NK T Cells. Journal of Immunology, 2003, 171, 4020-4027.	0.4	273
105	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 1-12.	4.8	273
106	NK Cell Maturation and Peripheral Homeostasis Is Associated with KLRG1 Up-Regulation. Journal of Immunology, 2007, 178, 4764-4770.	0.4	272
107	From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation, 2015, 125, 3338-3346.	3.9	271
108	NKT cells â€" conductors of tumor immunity?. Current Opinion in Immunology, 2002, 14, 165-171.	2.4	270

#	Article	IF	Citations
109	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 652-656.	3.3	270
110	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Research, 2018, 78, 1003-1016.	0.4	269
111	Mouse models in oncoimmunology. Nature Reviews Cancer, 2016, 16, 759-773.	12.8	267
112	A nonclassical non-VÎ±14JÎ±18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. Journal of Experimental Medicine, 2005, 202, 1627-1633.	4.2	262
113	Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function. Journal of Immunology, 2007, 178, 7540-7549.	0.4	261
114	Targeting Cancer-Derived Adenosine:New Therapeutic Approaches. Cancer Discovery, 2014, 4, 879-888.	7.7	256
115	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Journal of Clinical Investigation, 2013, 123, 1371-1381.	3.9	256
116	Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology, 2008, 84, 988-993.	1.5	253
117	TIM3⁺FOXP3⁺regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2, e23849.	2.1	251
118	Eradication of established tumors in mice by a combination antibody-based therapy. Nature Medicine, 2006, 12, 693-698.	15.2	248
119	Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research, 2012, 72, 3163-3174.	0.4	248
120	The NK cellâ€“cancer cycle: advances and new challenges in NK cellâ€“based immunotherapies. Nature Immunology, 2020, 21, 835-847.	7.0	243
121	TRAIL and its receptors as targets for cancer therapy. Cancer Science, 2004, 95, 777-783.	1.7	240
122	TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood, 2005, 105, 2082-2089.	0.6	237
123	A Network of PDZ-Containing Proteins Regulates T Cell Polarity and Morphology during Migration and Immunological Synapse Formation. Immunity, 2005, 22, 737-748.	6.6	237
124	Interleukin 15â€“mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nature Immunology, 2007, 8, 856-863.	7.0	231
125	Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma. Cancer Research, 2010, 70, 7788-7799.	0.4	228
126	Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and Î³Î´ T Cells. Journal of Experimental Medicine, 2004, 199, 879-884.	4.2	227

#	Article	IF	Citations
127	NKT cells are phenotypically and functionally diverse. European Journal of Immunology, 1999, 29, 3768-3781.	1.6	224
128	Functional subsets of mouse natural killer cells. Immunological Reviews, 2006, 214, 47-55.	2.8	222
129	Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor. Cancer Research, 2014, 74, 3652-3658.	0.4	217
130	Perforin is a major contributor to NK cell control of tumor metastasis. Journal of Immunology, 1999, 162, 6658-62.	0.4	214
131	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	6.6	207
132	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research, 2015, 75, 3800-3811.	0.4	201
133	Differential Recognition of CD1d-Î±-Galactosyl Ceramide by the VÎ²8.2 and VÎ²7 Semi-invariant NKT T Cell Receptors. Immunity, 2009, 31, 47-59.	6.6	198
134	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discovery, 2016, 6, 446-459.	7.7	198
135	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood, 2018, 132, 1689-1694.	0.6	198
136	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	3.3	195
137	Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy. Journal of Experimental Medicine, 2004, 199, 437-448.	4.2	193
138	NK Cell TRAIL Eliminates Immature Dendritic Cells In Vivo and Limits Dendritic Cell Vaccination Efficacy. Journal of Immunology, 2004, 172, 123-129.	0.4	191
139	Innate immunity defines the capacity of antiviral T cells to limit persistent infection. Journal of Experimental Medicine, 2010, 207, 1333-1343.	4.2	190
140	NKT cells and tumor immunityâ€"a double-edged sword. Nature Immunology, 2000, 1, 459-460.	7.0	188
141	Targeting CD39 in cancer. Nature Reviews Immunology, 2020, 20, 739-755.	10.6	185
142	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Seminars in Immunology, 2010, 22, 113-124.	2.7	183
143	Inflammation and immune surveillance in cancer. Seminars in Cancer Biology, 2012, 22, 23-32.	4.3	179
144	Targeting death-inducing receptors in cancer therapy. Oncogene, 2007, 26, 3745-3757.	2.6	178

#	Article	IF	Citations
145	Granzyme B Expression by CD8+ T Cells Is Required for the Development of Experimental Cerebral Malaria. Journal of Immunology, 2011, 186, 6148-6156.	0.4	178
146	CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research, 2012, 72, 2190-2196.	0.4	178
147	Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance. Journal of Immunology, 2007, 178, 4222-4229.	0.4	176
148	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery, 2019, 9, 1754-1773.	7.7	173
149	Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10306-10310.	3.3	172
150	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical Cancer Research, 2016, 22, 5183-5188.	3.2	171
151	Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications, 2017, 8, 592.	5.8	166
152	Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood, 2002, 100, 3155-3163.	0.6	165
153	Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth. Cancer Research, 2010, 70, 7800-7809.	0.4	165
154	NKT Cell Stimulation with Glycolipid Antigen In Vivo: Costimulation-Dependent Expansion, Bim-Dependent Contraction, and Hyporesponsiveness to Further Antigenic Challenge. Journal of Immunology, 2005, 175, 3092-3101.	0.4	163
155	Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death and Differentiation, 2014, 21, 5-14.	5.0	163
156	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5.	7.7	163
157	NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer. Journal of Experimental Medicine, 2004, 200, 1325-1335.	4.2	161
158	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
159	NLRP3 Suppresses NK Cellâ€"Mediated Responses to Carcinogen-Induced Tumors and Metastases. Cancer Research, 2012, 72, 5721-5732.	0.4	159
160	DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases. Journal of Immunology, 2010, 184, 902-911.	0.4	158
161	TRAIL+ NK Cells Control CD4+ T Cell Responses during Chronic Viral Infection to Limit Autoimmunity. Immunity, 2014, 41, 646-656.	6.6	158
162	Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. Journal of Experimental Medicine, 2005, 201, 1973-1985.	4.2	157

#	Article	IF	Citations
163	Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin. Journal of Immunology, 2002, 169, 5377-5381.	0.4	156
164	Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nature Communications, 2014, 5, 4539.	5.8	156
165	Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies. Journal of Immunology, 2005, 175, 5586-5590.	0.4	154
166	Cutting Edge: IL-21 Is Not Essential for Th17 Differentiation or Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 7097-7101.	0.4	154
167	BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. Clinical Microbiology Reviews, 2017, 30, 503-528.	5.7	154
168	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood, 2011, 117, 1605-1613.	0.6	152
169	Â-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9464-9469.	3.3	146
170	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	5.7	143
171	Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in NK Cell-Mediated and IFN-Î³-Dependent Suppression of Subcutaneous Tumor Growth. Cellular Immunology, 2001, 214, 194-200.	1.4	142
172	IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood, 2002, 100, 1728-33.	0.6	140
173	Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood, 2010, 116, 819-828.	0.6	139
174	Supernatural T cells: genetic modification of T cells for cancer therapy. Nature Reviews Immunology, 2005, 5, 928-940.	10.6	137
175	Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19051-19056.	3.3	136
176	Efficient Nuclear Targeting of Granzyme B and the Nuclear Consequences of Apoptosis Induced by Granzyme B and Perforin Are Caspase-dependent, but Cell Death Is Caspase-independent. Journal of Biological Chemistry, 1998, 273, 27934-27938.	1.6	135
177	Perforin and Granzymes Have Distinct Roles in Defensive Immunity and Immunopathology. Immunity, 2006, 25, 835-848.	6.6	134
178	A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood, 2011, 117, 1869-1879.	0.6	134
179	Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. International Immunology, 2001, 13, 887-896.	1.8	133
180	Interleukin-21-Producing CD4+ T Cells Promote Type 2 Immunity to House Dust Mites. Immunity, 2015, 43, 318-330.	6.6	132

#	Article	IF	Citations
181	Calcium-dependent Plasma Membrane Binding and Cell Lysis by Perforin Are Mediated through Its C2 Domain. Journal of Biological Chemistry, 2005, 280, 8426-8434.	1.6	131
182	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 2021, 184, 2167-2182.e22.	13.5	131
183	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Research, 2016, 76, 4372-4382.	0.4	130
184	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11317-11322.	3.3	129
185	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 2019, 25, 5743-5751.	3.2	129
186	Fatal Hepatitis Mediated by Tumor Necrosis Factor TNFÎ± Requires Caspase-8 and Involves the BH3-Only Proteins Bid and Bim. Immunity, 2009, 30, 56-66.	6.6	128
187	Functional dissection of the granzyme family: cell death and inflammation. Immunological Reviews, 2010, 235, 73-92.	2.8	128
188	Targeting cancerâ€related inflammation in the era of immunotherapy. Immunology and Cell Biology, 2017, 95, 325-332.	1.0	128
189	Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Current Opinion in Immunology, 2000, 12, 323-329.	2.4	127
190	Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer and Metastasis Reviews, 2011, 30, 125-140.	2.7	127
191	An Essential Role for Tumor Necrosis Factor in Natural Killer Cellâ€"mediated Tumor Rejection in the Peritoneum. Journal of Experimental Medicine, 1998, 188, 1611-1619.	4.2	126
192	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Research, 2017, 77, 4697-4709.	0.4	126
193	Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-Î¶ vs FcÎµRI-Î³. Journal of Immunology, 2001, 166, 182-187.	0.4	125
194	IFN-Î³ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications, 2017, 8, 14607.	5.8	125
195	Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10895-10900.	3.3	124
196	Activation of Natural Killer (NK) T Cells during Murine Cytomegalovirus Infection Enhances the Antiviral Response Mediated by NK Cells. Journal of Virology, 2003, 77, 1877-1884.	1.5	123
197	Apoptosis induced by the lymphocyte effector molecule perforin. Current Opinion in Immunology, 2007, 19, 339-347.	2.4	123
198	Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin. Journal of Immunology, 2002, 168, 3484-3492.	0.4	121

#	Article	IF	Citations
199	IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism. Journal of Immunology, 2005, 175, 2167-2173.	0.4	121
200	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
201	Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood, 2018, 132, 1675-1688.	0.6	119
202	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. Cancer Research, 2014, 74, 436-445.	0.4	118
203	Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. Journal of Immunology, 1991, 146, 3289-97.	0.4	118
204	Asymmetric Cell Division of T Cells upon Antigen Presentation Uses Multiple Conserved Mechanisms. Journal of Immunology, 2010, 185, 367-375.	0.4	117
205	CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nature Communications, 2015, 6, 8644.	5.8	117
206	IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8328-8333.	3.3	116
207	DNAMâ€1 control of natural killer cells functions through nectin and nectinâ€like proteins. Immunology and Cell Biology, 2014, 92, 237-244.	1.0	115
208	NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. Journal of Clinical Investigation, 2005, 115, 3093-3103.	3.9	114
209	Granzyme M Mediates a Novel Form of Perforin-dependent Cell Death. Journal of Biological Chemistry, 2004, 279, 22236-22242.	1.6	113
210	Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nature Medicine, 2007, 13, 1308-1315.	15.2	112
211	An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. Cancer Research, 2013, 73, 7265-7276.	0.4	112
212	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. Molecular Therapy, 2014, 22, 18-27.	3.7	112
213	Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Research, 2011, 71, 6567-6571.	0.4	111
214	Differential Requirement for Nfil3 during NK Cell Development. Journal of Immunology, 2014, 192, 2667-2676.	0.4	111
215	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	3.9	111
216	DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation. Cell Reports, 2015, 11, 85-97.	2.9	111

#	Article	IF	Citations
217	The Interactions of Multiple Cytokines Control NK Cell Maturation. Journal of Immunology, 2010, 185, 6679-6688.	0.4	110
218	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nature Immunology, 2020, 21, 1205-1218.	7.0	110
219	Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells.. Journal of Experimental Medicine, 1990, 171, 1269-1281.	4.2	109
220	Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo.. Journal of Experimental Medicine, 1990, 172, 1877-1880.	4.2	108
221	Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. Journal of Experimental Medicine, 2007, 204, 2579-2590.	4.2	108
222	A role for CCL2 in both tumor progression and immunosurveillance. OncoImmunology, 2013, 2, e25474.	2.1	108
223	A Role for P-Glycoprotein in Regulating Cell Death. Leukemia and Lymphoma, 2000, 38, 1-11.	0.6	105
224	The Influence of CD1d in Postselection NKT Cell Maturation and Homeostasis. Journal of Immunology, 2005, 175, 3762-3768.	0.4	105
225	A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. Journal of Experimental Medicine, 2006, 203, 661-673.	4.2	105
226	Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Therapy, 2010, 17, 678-686.	2.3	105
227	G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7077-7082.	3.3	105
228	ATP and cancer immunosurveillance. EMBO Journal, 2021, 40, e108130.	3.5	105
229	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation, 2003, 111, 1161-1170.	3.9	105
230	Unlocking the secrets of cytotoxic granule proteins. Journal of Leukocyte Biology, 2001, 70, 18-29.	1.5	104
231	Immunogenic anti-cancer chemotherapy as an emerging concept. Current Opinion in Immunology, 2008, 20, 545-557.	2.4	101
232	The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15. Immunity, 2016, 44, 103-115.	6.6	101
233	MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1. Cancer Discovery, 2020, 10, 124-141.	7.7	101
234	Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood, 2005, 106, 2995-3003.	0.6	100

#	Article	IF	Citations
235	Limited correlation between human thymus and blood NKT?cell content revealed by an ontogeny study of paired tissue samples. European Journal of Immunology, 2005, 35, 1399-1407.	1.6	100
236	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cellular and Molecular Life Sciences, 2016, 73, 1569-1589.	2.4	100
237	Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood, 2009, 113, 6382-6385.	0.6	99
238	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nature Cell Biology, 2013, 15, 818-828.	4.6	99
239	Interleukin 2 Receptor Signaling Regulates the Perforin Gene through Signal Transducer and Activator of Transcription (Stat)5 Activation of Two Enhancers. Journal of Experimental Medicine, 1999, 190, 1297-1308.	4.2	98
240	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4141-4146.	3.3	98
241	A balance of interleukin-12 and -23 in cancer. Trends in Immunology, 2013, 34, 548-555.	2.9	98
242	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood, 2015, 126, 1609-1620.	0.6	98
243	Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. Cancer Immunology Research, 2017, 5, 1098-1108.	1.6	98
244	Localization of Granzyme B in the Nucleus. Journal of Biological Chemistry, 1996, 271, 4127-4133.	1.6	97
245	NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International Immunology, 2008, 20, 631-631.	1.8	97
246	A semi-invariant VÎ±10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigenâ€"recognition properties. Nature Immunology, 2011, 12, 616-623.	7.0	97
247	Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation. Journal of Immunology, 2002, 169, 5780-5786.	0.4	96
248	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. Cancer Research, 2014, 74, 7298-7308.	0.4	96
249	Long-Term Retention of Mature NK1.1+ NKT Cells in the Thymus. Journal of Immunology, 2006, 176, 4059-4065.	0.4	95
250	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	3.2	95
251	Oncolytic Virus and Antiâ€"4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research, 2012, 72, 1651-1660.	0.4	94
252	Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028530.	2.3	94

#	Article	IF	Citations
253	Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death and Differentiation, 2004, 11, 1028-1037.	5.0	93
254	The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood, 2003, 101, 3590-3593.	0.6	92
255	Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research, 2012, 72, 3987-3996.	0.4	92
256	Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. PLoS Pathogens, 2016, 12, e1005398.	2.1	92
257	The Role of NK Cells in Autoimmune Disease. Autoimmunity, 2002, 35, 1-14.	1.2	91
258	KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Experimental Hematology, 2005, 33, 1160-1171.	0.2	91
259	Differential lymphotoxin-? and interferon gamma signaling during mouse liver regeneration induced by chronic and acute injury. Hepatology, 2005, 41, 327-335.	3.6	91
260	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Journal of Clinical Investigation, 2018, 128, 2613-2625.	3.9	91
261	Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2016, 103, 62-77.	2.0	90
262	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 2017, 77, 5652-5663.	0.4	90
263	CTL granules: evolution of vesicles essential for combating virus infections. Trends in Immunology, 1999, 20, 351-356.	7.5	89
264	Cross-talk between dendritic cells and natural killer cells in viral infection. Molecular Immunology, 2005, 42, 547-555.	1.0	89
265	P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood, 1999, 93, 1075-85.	0.6	89
266	The Restricted Expression of Granzyme M in Human Lymphocytes. Journal of Immunology, 2001, 166, 765-771.	0.4	88
267	Interleukin 21: combination strategies for cancer therapy. Nature Reviews Drug Discovery, 2008, 7, 231-240.	21.5	88
268	Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Current Opinion in Immunology, 2012, 24, 246-251.	2.4	88
269	Transforming growth factorâ€“Î² and Notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Science Signaling, 2016, 9, ra46.	1.6	88
270	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research, 2020, 26, 5520-5533.	3.2	88

#	Article	IF	Citations
271	Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I. Journal of Immunology, 1995, 154, 6299-305.	0.4	88
272	Contribution of Thy1⁺NK cells to protective IFN-Î³ production during<i>Salmonella</i>Typhimurium infections. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2252-2257.	3.3	87
273	Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection. Journal of Immunology, 2003, 171, 515-518.	0.4	86
274	Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy. Journal of Immunology, 2009, 182, 5217-5224.	0.4	86
275	Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. Journal of Experimental Medicine, 2015, 212, 1303-1321.	4.2	85
276	Tumor intrinsic and extrinsic immune functions of CD155. Seminars in Cancer Biology, 2020, 65, 189-196.	4.3	85
277	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity, 2020, 53, 824-839.e10.	6.6	85
278	NK cell heparanase controls tumor invasion and immune surveillance. Journal of Clinical Investigation, 2017, 127, 2777-2788.	3.9	85
279	Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Research, 2003, 63, 207-13.	0.4	85
280	Cancer immunoediting and immune dysregulation in multiple myeloma. Blood, 2020, 136, 2731-2740.	0.6	84
281	TNFâ€related apoptosisâ€inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunology and Cell Biology, 2006, 84, 87-98.	1.0	83
282	Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody. Journal of the National Cancer Institute, 2008, 100, 649-662.	3.0	83
283	Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potentin vivo anti-tumor capacity. European Journal of Immunology, 2001, 31, 39-47.	1.6	82
284	NK cells require IL-28R for optimal in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2376-84.	3.3	82
285	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. Cancer Research, 2016, 76, 5288-5301.	0.4	82
286	Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth. PLoS ONE, 2009, 4, e6982.	1.1	82
287	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research, 2017, 77, 4684-4696.	0.4	80
288	Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Journal of Leukocyte Biology, 1996, 60, 555-562.	1.5	79

#	Article	IF	Citations
289	Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL. Journal of Immunology, 2000, 164, 3705-3712.	0.4	79
290	Fas ligandâ€"mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nature Medicine, 2014, 20, 283-290.	15.2	79
291	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research, 2019, 7, 559-571.	1.6	79
292	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	6.6	79
293	NKG2D and cytotoxic effector function in tumor immune surveillance. Seminars in Immunology, 2006, 18, 176-185.	2.7	78
294	From cancer immunosurveillance to cancer immunotherapy. Immunological Reviews, 2007, 220, 82-101.	2.8	78
295	IFN-Î³ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. Journal of Leukocyte Biology, 2011, 90, 777-785.	1.5	78
296	Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer. Journal of Immunology, 2004, 173, 2143-2150.	0.4	77
297	Interleukin-21 Signaling: Functions in Cancer and Autoimmunity. Clinical Cancer Research, 2007, 13, 6926-6932.	3.2	77
298	A Role for Granzyme M in TLR4-Driven Inflammation and Endotoxicosis. Journal of Immunology, 2010, 185, 1794-1803.	0.4	77
299	Roles of the RANKLâ€"RANK axis in antitumour immunity â€" implications for therapy. Nature Reviews Clinical Oncology, 2018, 15, 676-693.	12.5	77
300	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood, 2000, 95, 2378-2385.	0.6	76
301	Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules. Journal of Immunology, 2010, 184, 5493-5501.	0.4	76
302	NK Cells and Cancer Immunoediting. Current Topics in Microbiology and Immunology, 2015, 395, 115-145.	0.7	76
303	M144, a Murine Cytomegalovirus (Mcmv)-Encoded Major Histocompatibility Complex Class I Homologue, Confers Tumor Resistance to Natural Killer Cellâ€"Mediated Rejection. Journal of Experimental Medicine, 1999, 190, 435-444.	4.2	74
304	P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death and Differentiation, 2002, 9, 1266-1272.	5.0	74
305	α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]. Current Medicinal Chemistry, 2004, 11, 241-252.	1.2	74
306	Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy, 2011, 60, 671-683.	2.0	74

#	Article	IF	Citations
307	NLRP3 promotes inflammationâ€induced skin cancer but is dispensable for asbestosâ€induced mesothelioma. Immunology and Cell Biology, 2012, 90, 983-986.	1.0	74
308	The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology, 2014, 3, e27414.	2.1	74
309	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cellâ€“Rich Tumor. Cancer Research, 2016, 76, 6266-6277.	0.4	74
310	Application of CD27 as a marker for distinguishing human NK cell subsets. International Immunology, 2008, 20, 625-630.	1.8	73
311	Allergen-induced IL-6 trans-signaling activates Î³Î´ T cells to promote type 2 and type 17 airway inflammation. Journal of Allergy and Clinical Immunology, 2015, 136, 1065-1073.	1.5	73
312	Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. International Journal of Cancer, 2002, 99, 292-298.	2.3	72
313	Plasmodium Strain Determines Dendritic Cell Function Essential for Survival from Malaria. PLoS Pathogens, 2007, 3, e96.	2.1	72
314	Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. International Journal of Biochemistry and Cell Biology, 2007, 39, 280-286.	1.2	72
315	Normal Thymocyte Negative Selection in TRAIL-deficient Mice. Journal of Experimental Medicine, 2003, 198, 491-496.	4.2	71
316	Calreticulin exposure increases cancer immunogenicity. Nature Biotechnology, 2007, 25, 192-193.	9.4	71
317	Bench to bedside: NK cells and control of metastasis. Clinical Immunology, 2017, 177, 50-59.	1.4	71
318	Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death and Differentiation, 1998, 5, 488-496.	5.0	70
319	Reversal in the Immunodominance Hierarchy in Secondary CD8+ T Cell Responses to Influenza A Virus: Roles for Cross-Presentation and Lysis-Independent Immunodomination. Journal of Immunology, 2004, 173, 5021-5027.	0.4	70
320	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clinical Cancer Research, 2017, 23, 5789-5801.	3.2	70
321	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 2019, 8, e1581530.	2.1	69
322	The role of natural killer cells in tumor controlâ€”effectors and regulators of adaptive immunity. Seminars in Immunopathology, 2005, 27, 49-64.	4.0	68
323	SnapShot: Extrinsic Apoptosis Pathways. Cell, 2010, 143, 1192-1192.e2.	13.5	68
324	CD3^{bright} signals on Î³Î´ T cells identify ILâ€•17Aâ€•producing VÎ³6VÎ´1⁺ T cells. Immunology and Cell Biology, 2015, 93, 198-212.	1.0	68

#	Article	IF	Citations
325	NK cells and apoptosis. Immunology and Cell Biology, 1999, 77, 64-75.	1.0	67
326	The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene. Journal of Experimental Medicine, 2004, 200, 811-816.	4.2	67
327	Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion. Cancer Research, 2010, 70, 2665-2674.	0.4	67
328	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood, 2012, 120, 3019-3029.	0.6	67
329	Peripheral natural killer cell maturation depends on the transcription factor Aiolos. EMBO Journal, 2014, 33, 2721-2734.	3.5	67
330	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 2018, 7, e1431088.	2.1	67
331	Functional Analysis of Granzyme M and Its Role in Immunity to Infection. Journal of Immunology, 2005, 175, 3235-3243.	0.4	66
332	Targeting immune checkpoints in hematological malignancies. Journal of Hematology and Oncology, 2020, 13, 111.	6.9	66
333	CD1-Restricted T Cells and Tumor Immunity. , 2007, 314, 293-323.		66
334	Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, e104-e106.	0.8	65
335	Immunopurification of Functional Asp-ase (Natural Killer Cell Granzyme B) Using a Monoclonal Antibody. Biochemical and Biophysical Research Communications, 1993, 195, 910-920.	1.0	64
336	Combined Natural Killer T-Cellâ€“Based Immunotherapy Eradicates Established Tumors in Mice. Cancer Research, 2007, 67, 7495-7504.	0.4	64
337	Induction of natural killer T cellâ€“dependent alloreactivity by administration of granulocyte colonyâ€“stimulating factor after bone marrow transplantation. Nature Medicine, 2009, 15, 436-441.	15.2	64
338	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clinical and Translational Immunology, 2014, 3, e22.	1.7	64
339	The role of NK cells and CD39 in the immunological control of tumor metastases. OncoImmunology, 2019, 8, e1593809.	2.1	64
340	Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. OncoImmunology, 2013, 2, e22355.	2.1	63
341	Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. Journal of Immunology, 1992, 149, 949-56.	0.4	63
342	A Role for IFN-Î³ in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo. Journal of Immunology, 2002, 168, 4472-4479.	0.4	62

#	Article	IF	Citations
343	Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo. Journal of Immunology, 2008, 181, 3449-3455.	0.4	62
344	The Relative Role of Lymphocyte Granule Exocytosis versus Death Receptor-Mediated Cytotoxicity in Viral Pathophysiology. Journal of Virology, 1998, 72, 1-9.	1.5	62
345	TNFâ€related apoptosisâ€inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunology and Cell Biology, 2005, 83, 511-519.	1.0	61
346	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. Cancer Research, 2018, 78, 475-488.	0.4	61
347	Peripheral NK1.1â^' NKT Cells Are Mature and Functionally Distinct from Their Thymic Counterparts. Journal of Immunology, 2007, 179, 6630-6637.	0.4	60
348	Multiple functions of CXCL12 in a syngeneic model of breast cancer. Molecular Cancer, 2010, 9, 250.	7.9	60
349	Control of Metastases via Myeloid CD39 and NK Cell Effector Function. Cancer Immunology Research, 2020, 8, 356-367.	1.6	60
350	Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells. Cancer Research, 2007, 67, 11428-11437.	0.4	59
351	CD4 ⁺ Natural Killer T Cells Potently Augment Aortic Root Atherosclerosis by Perforin- and Granzyme B-Dependent Cytotoxicity. Circulation Research, 2015, 116, 245-254.	2.0	59
352	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Medicine, 2016, 8, 111.	3.6	59
353	IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. Journal of Immunology, 1990, 145, 1159-66.	0.4	59
354	The mTORC1 Inhibitor Everolimus Prevents and Treats EÎ¼-<i>Myc</i> Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery, 2013, 3, 82-95.	7.7	58
355	Radiotherapy Complements Immune Checkpoint Blockade. Cancer Cell, 2015, 27, 437-438.	7.7	58
356	Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. European Journal of Immunology, 1998, 28, 1663-1672.	1.6	57
357	Intrathymic NKT cell development is blocked by the presence of Î±-galactosylceramide. European Journal of Immunology, 2003, 33, 1816-1823.	1.6	56
358	IFN-Â-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood, 2005, 106, 184-192.	0.6	56
359	The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum. Journal of Immunotherapy, 2009, 32, 292-301.	1.2	56
360	Dietary<i>Lactobacillus</i>-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy. Cancer Discovery, 2022, 12, 1336-1355.	7.7	56

#	Article	IF	Citations
361	Tumor Necrosis Factor Sustains the Generalized Lymphoproliferative Disorder (gld) Phenotype. Journal of Experimental Medicine, 2000, 191, 89-96.	4.2	55
362	A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Therapy, 2004, 11, 371-379.	2.2	55
363	Innate Immune Recognition and Suppression of Tumors. Advances in Cancer Research, 2006, 95, 293-322.	1.9	55
364	IFN-Î³-Dependent Recruitment of Mature CD27high NK Cells to Lymph Nodes Primed by Dendritic Cells. Journal of Immunology, 2008, 181, 5323-5330.	0.4	55
365	Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunology and Cell Biology, 2004, 82, 323-331.	1.0	54
366	Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. Journal of Clinical Investigation, 2013, 123, 5351-5360.	3.9	54
367	Activation of Invariant NKT Cells Exacerbates Experimental Visceral Leishmaniasis. PLoS Pathogens, 2008, 4, e1000028.	2.1	53
368	Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. OncoImmunology, 2017, 6, e1267892.	2.1	53
369	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	3.2	53
370	Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation, 2005, 73, 142-153.	1.0	52
371	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cellâ€"Mediated Immunotherapy. Cancer Research, 2017, 77, 4434-4447.	0.4	52
372	IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection. PLoS Pathogens, 2016, 12, e1005999.	2.1	52
373	The roles of interferonâ€Î³ and perforin in antiviral immunity in mice that differ in genetically determined NKâ€cellâ€mediated antiviral activity. Immunology and Cell Biology, 2009, 87, 559-566.	1.0	51
374	Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. Journal of Immunology, 1991, 146, 3791-8.	0.4	51
375	Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. ELife, 2017, 6, .	2.8	50
376	IL-7 regulation of cytotoxic lymphocytes: Pore-forming protein gene expression, interferon-Î³ production, and cytotoxicity of human peripheral blood lymphocyte subsets. Cellular Immunology, 1991, 138, 390-403.	1.4	49
377	Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunology and Cell Biology, 2004, 82, 247-252.	1.0	49
378	CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors. Journal of Immunology, 2010, 185, 532-541.	0.4	49

#	Article	IF	Citations
379	Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity. Cancer Research, 2010, 70, 9591-9598.	0.4	49
380	Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nature Immunology, 2012, 13, 1171-1177.	7.0	49
381	Bone marrow transplantation generates T cellâ€"dependent control of myeloma in mice. Journal of Clinical Investigation, 2018, 129, 106-121.	3.9	49
382	Role of TNF in lymphocyte-mediated cytotoxicity. Microscopy Research and Technique, 2000, 50, 196-208.	1.2	48
383	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. OncoImmunology, 2018, 7, e1480301.	2.1	48
384	Met-ase: cloning and distinct chromosomal location of a serine protease preferentially expressed in human natural killer cells. Journal of Immunology, 1993, 151, 6195-205.	0.4	48
385	Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. Cell Death and Differentiation, 2000, 7, 973-983.	5.0	47
386	Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood, 2013, 121, 3511-3520.	0.6	47
387	Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Advances, 2018, 2, 335-346.	2.5	47
388	Anti-IL-23 Monoclonal Antibody Synergizes in Combination with Targeted Therapies or IL-2 to Suppress Tumor Growth and Metastases. Cancer Research, 2011, 71, 2077-2086.	0.4	46
389	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. OncoImmunology, 2018, 7, e1445949.	2.1	46
390	Immunotherapy of Cancer Using Systemically Delivered Gene-Modified Human T Lymphocytes. Human Gene Therapy, 2004, 15, 699-708.	1.4	45
391	NK cells contribute to the early clearance of HSV-1 from the lung but cannot control replication in the central nervous system following intranasal infection. European Journal of Immunology, 2006, 36, 897-905.	1.6	45
392	Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma. Cancer Research, 2007, 67, 5454-5460.	0.4	45
393	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16254-16259.	3.3	45
394	Cutting Edge: Novel Priming of Tumor-Specific Immunity by NKG2D-Triggered NK Cell-Mediated Tumor Rejection and Th1-Independent CD4+ T Cell Pathway. Journal of Immunology, 2004, 172, 757-761.	0.4	44
395	Role of Î³Î´ T Cells in Î±-Galactosylceramideâ€"Mediated Immunity. Journal of Immunology, 2012, 188, 3928-3939.	0.4	44
396	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. OncoImmunology, 2018, 7, e1424677.	2.1	44

#	Article	IF	Citations
397	Cancer vaccines for established cancer: how to make them better?. Immunological Reviews, 2008, 222, 242-255.	2.8	43
398	Transient Foxp3⁺ regulatory Tâ€cell depletion enhances therapeutic anticancer vaccination targeting the immuneâ€stimulatory properties of NKT cells. Immunology and Cell Biology, 2013, 91, 105-114.	1.0	43
399	Purification and cloning of a novel serine protease, RNK-Met-1, from the granules of a rat natural killer cell leukemia. Journal of Biological Chemistry, 1992, 267, 24418-25.	1.6	43
400	Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors. Nature Immunology, 2004, 5, 590-596.	7.0	42
401	Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 2019, 8, e1546068.	2.1	42
402	Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Research, 2003, 63, 3058-60.	0.4	42
403	Killing by cytotoxic T cells and natural killer cells: Multiple granule serine proteases as initiators of DNA fragmentation. Immunology and Cell Biology, 1993, 71, 201-208.	1.0	41
404	Lymphocyte-mediated immunosurveillance of epithelial cancers?. Trends in Immunology, 2001, 22, 409-411.	2.9	41
405	Parallels and distinctions between T and NKT cell development in the thymus. Immunology and Cell Biology, 2004, 82, 269-275.	1.0	41
406	Dihydrofuro[3,4<i>-c</i>]pyridinones as Inhibitors of the Cytolytic Effects of the Pore-Forming Glycoprotein Perforin. Journal of Medicinal Chemistry, 2008, 51, 7614-7624.	2.9	41
407	2018 Nobel Prize in physiology or medicine. Clinical and Translational Immunology, 2018, 7, e1041.	1.7	41
408	Working with NKT cells â€" pitfalls and practicalities. Current Opinion in Immunology, 2005, 17, 448-454.	2.4	40
409	Perforin-mediated suppression of B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2723-2728.	3.3	40
410	DX5/CD49b-Positive T Cells Are Not Synonymous with CD1d-Dependent NKT Cells. Journal of Immunology, 2005, 175, 4416-4425.	0.4	39
411	NKG2A Inhibits Invariant NKT Cell Activation in Hepatic Injury. Journal of Immunology, 2009, 182, 250-258.	0.4	39
412	A potential role for RAGâ€1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunology and Cell Biology, 2010, 88, 107-116.	1.0	39
413	Cutting Edge: DNAX Accessory Molecule 1â€"Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity. Journal of Immunology, 2014, 192, 553-557.	0.4	39
414	IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy. Journal of Immunology, 2006, 176, 6347-6355.	0.4	38

#	Article	IF	Citations
415	Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy, 2010, 17, 1105-1116.	2.3	38
416	Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. European Journal of Immunology, 2014, 44, 1016-1030.	1.6	38
417	NKT cells are not critical for HSVâ€1 disease resolution. Immunology and Cell Biology, 2006, 84, 13-19.	1.0	37
418	Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica, 2007, 92, 1075-1082.	1.7	36
419	The granzyme B-Serpinb9 axis controls the fate of lymphocytes after lysosomal stress. Cell Death and Differentiation, 2014, 21, 876-887.	5.0	36
420	XENOSPECIFIC CYTOTOXIC T LYMPHOCYTES USE PERFORIN-AND FAS-MEDIATED LYTIC PATHWAYS1. Transplantation, 1996, 62, 1529-1532.	0.5	36
421	Making Macrophages Eat Cancer. Science, 2013, 341, 41-42.	6.0	35
422	Interleukin 21: A Key Player in Lymphocyte Maturation. Critical Reviews in Immunology, 2004, 24, 239-250.	1.0	35
423	CD1d Activation and Blockade: A New Antitumor Strategy. Journal of Immunology, 2009, 182, 3366-3371.	0.4	34
424	Influenza A Infection Enhances Cross-Priming of CD8+T Cells to Cell-Associated Antigens in a TLR7- and Type I IFN-Dependent Fashion. Journal of Immunology, 2010, 185, 6013-6022.	0.4	34
425	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Cell Reports, 2020, 30, 2512-2525.e9.	2.9	34
426	Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. Journal of the National Cancer Institute, 1987, 79, 1367-73.	3.0	34
427	The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics, 1994, 40, 235-237.	1.2	33
428	Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. Journal of Immunology, 1992, 148, 55-62.	0.4	33
429	Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. Journal of Immunology, 1999, 163, 1350-3.	0.4	33
430	Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology. Current Topics in Microbiology and Immunology, 2010, 344, 61-95.	0.7	32
431	Combined Anti-CD40 and Antiâ€"IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases. Cancer Research, 2014, 74, 2412-2421.	0.4	32
432	Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF^{V600E} melanoma. OncoImmunology, 2016, 5, e1089381.	2.1	32

#	Article	IF	Citations
433	GVHD prevents NK-cellâ€"dependent leukemia and virus-specific innate immunity. Blood, 2017, 129, 630-642.	0.6	32
434	Purification of a factor from the granules of a rat natural killer cell line (RNK) that reduces tumor cell growth and changes tumor morphology. Molecular identity with a granule serine protease (RNKP-1). Journal of Immunology, 1992, 148, 292-300.	0.4	32
435	Chemoimmunoconjugates for the Treatment of Cancer. Advances in Immunology, 1994, 56, 301-387.	1.1	31
436	The Elusive NKT Cell Antigen--Is the Search Over?. Science, 2004, 306, 1687-1689.	6.0	31
437	Redundancy in the immune system restricts the spread of HSV-1 in the central nervous system (CNS) of C57BL/6 mice. Virology, 2010, 400, 248-258.	1.1	31
438	Stable IL-10: A New Therapeutic that Promotes Tumor Immunity. Cancer Cell, 2011, 20, 691-693.	7.7	31
439	Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. OncoImmunology, 2015, 4, e1027468.	2.1	31
440	Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. OncoImmunology, 2019, 8, e1648171.	2.1	31
441	Delayed kinetics of tumor necrosis factor-mediated bystander lysis by peptide-specific CD8+ cytotoxic T lymphocytes. European Journal of Immunology, 1998, 28, 4162-4169.	1.6	30
442	Blastocyst MHC, a Putative Murine Homologue of HLA-G, Protects TAP-Deficient Tumor Cells from Natural Killer Cell-Mediated Rejection In Vivo. Journal of Immunology, 2003, 171, 1715-1721.	0.4	30
443	Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24.	1.1	30
444	Autophagy and proteasome interconnect to coordinate crossâ€presentation through MHC class I pathway in B cells. Immunology and Cell Biology, 2016, 94, 964-974.	1.0	30
445	TREM2 marks tumor-associated macrophages. Signal Transduction and Targeted Therapy, 2020, 5, 233.	7.1	30
446	Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes. Journal of Immunology, 1991, 146, 1380-4.	0.4	30
447	Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Research, 1988, 48, 3607-12.	0.4	30
448	Granule serine proteases are normal nuclear constituents of natural killer cells. Journal of Biological Chemistry, 1994, 269, 18359-65.	1.6	30
449	Does IL-17 suppress tumor growth?. Blood, 2010, 115, 2554-2555.	0.6	29
450	Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death and Differentiation, 2014, 21, 50-58.	5.0	29

#	Article	IF	Citations
451	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumorâ€infiltrating TÂcells. Immunology and Cell Biology, 2019, 97, 152-164.	1.0	29
452	The use of chimeric human FcÎµ receptor I to redirect cytotoxic T lymphocytes to tumors. Journal of Leukocyte Biology, 1996, 60, 721-728.	1.5	28
453	Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy, 1999, 47, 278-286.	2.0	28
454	Can NK cells be a therapeutic target in human diseases?. European Journal of Immunology, 2008, 38, 2964-2968.	1.6	28
455	Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo. Journal of Biological Chemistry, 2008, 283, 30850-30860.	1.6	28
456	CD1d-Based Combination Therapy Eradicates Established Tumors in Mice. Journal of Immunology, 2009, 183, 1911-1920.	0.4	28
457	Invariant natural killer T cellâ€"natural killer cell interactions dictate transplantation outcome after Î±-galactosylceramide administration. Blood, 2009, 113, 5999-6010.	0.6	28
458	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. Blood Advances, 2017, 1, 341-351.	2.5	28
459	Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade. Cancer Discovery, 2018, 8, 1066-1068.	7.7	28
460	XENOSPECIFIC CYTOTOXIC T LYMPHOCYTES. Transplantation, 1997, 63, 1171-1178.	0.5	28
461	Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. Journal of the National Cancer Institute, 1986, 76, 503-10.	3.0	28
462	Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Research, 1987, 47, 62-9.	0.4	28
463	A novel substrate-binding pocket interaction restricts the specificity of the human NK cell-specific serine protease, Met-ase-1. Journal of Immunology, 1996, 156, 4174-81.	0.4	28
464	Cloning and expression of the recombinant mouse natural killer cell granzymeMet-ase-1. Immunogenetics, 1996, 44, 340-350.	1.2	27
465	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity, 2020, 53, 564-580.e9.	6.6	27
466	Targeting an adenosine-mediated â€œdonâ€™t eat me signalâ€• augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 2020, 34, 2708-2721.	3.3	27
467	Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Research, 1988, 48, 926-31.	0.4	27
468	The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunology and Cell Biology, 1987, 65, 111-125.	1.0	26

#	Article	IF	Citations
469	P-glycoprotein Does Not Protect Cells against Cytolysis Induced by Pore-forming Proteins. Journal of Biological Chemistry, 2001, 276, 16667-16673.	1.6	26
470	Subset Analysis of Human and Mouse Mature NK Cells. Methods in Molecular Biology, 2010, 612, 27-38.	0.4	26
471	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. OncoImmunology, 2018, 7, e1386826.	2.1	26
472	Hide and seek: Plasticity of innate lymphoid cells in cancer. Seminars in Immunology, 2019, 41, 101273.	2.7	26
473	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery, 2019, 9, 1511-1519.	7.7	26
474	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood, 2000, 95, 2378-85.	0.6	26
475	Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. Journal of Leukocyte Biology, 1996, 59, 763-768.	1.5	25
476	Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy, 2008, 15, 1056-1066.	2.3	25
477	SOCS-1 Binding to Tyrosine 441 of IFN-Î³ Receptor Subunit 1 Contributes to the Attenuation of IFN-Î³ Signaling In Vivo. Journal of Immunology, 2009, 183, 4537-4544.	0.4	25
478	Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunology, Immunotherapy, 2012, 61, 1255-1268.	2.0	25
479	IL-17Aâ€"Producing Î³Î´ T Cells Suppress Early Control of Parasite Growth by Monocytes in the Liver. Journal of Immunology, 2015, 195, 5707-5717.	0.4	25
480	Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. OncoImmunology, 2017, 6, e1312044.	2.1	25
481	ACKR4 restrains antitumor immunity by regulating CCL21. Journal of Experimental Medicine, 2020, 217, .	4.2	25
482	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood, 2000, 95, 2378-2385.	0.6	25
483	Expression of Recombinant Human MET-ASE-1: A NK Cell-Specific Granzyme. Biochemical and Biophysical Research Communications, 1995, 217, 675-683.	1.0	24
484	Type I interferon and cancer immunoediting. Nature Immunology, 2005, 6, 646-648.	7.0	24
485	Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Therapy, 2007, 14, 499-508.	2.2	24
486	Interleukin 21 Enhances Antibody-Mediated Tumor Rejection. Cancer Research, 2008, 68, 3019-3025.	0.4	24

#	Article	IF	Citations
487	Chemokineâ€"chemokine receptors in cancer immunotherapy. Immunotherapy, 2009, 1, 109-127.	1.0	24
488	Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. Journal of Translational Medicine, 2010, 8, 42.	1.8	24
489	The Adjuvant Effects of Antibodies. Science, 2011, 333, 944-945.	6.0	24
490	Targeting regulatory T cells in tumor immunotherapy. Immunology and Cell Biology, 2014, 92, 473-474.	1.0	24
491	Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 2019, 3, 1681-1694.	2.5	24
492	Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. Journal of Immunology, 1997, 158, 5765-72.	0.4	24
493	Adoptive Transfer of Chimeric Fc Îµ RI Receptor Gene-Modified Human T Cells for Cancer Immunotherapy. Human Gene Therapy, 2006, 17, 1134-1143.	1.4	23
494	Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunology, Immunotherapy, 2010, 59, 1235-1246.	2.0	23
495	Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. OncoImmunology, 2013, 2, e24786.	2.1	23
496	DNAM-1: would the real natural killer cell please stand up!. Oncotarget, 2015, 6, 28537-28538.	0.8	23
497	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research, 2017, 77, 2594-2606.	0.4	23
498	Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8⁺Cytotoxic T Lymphocytes. Journal of Virology, 1998, 72, 5948-5954.	1.5	23
499	Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clinical Cancer Research, 2009, 15, 7624-7633.	3.2	22
500	Co-blockade of immune checkpoints and adenosine A_{2A}receptor suppresses metastasis. OncoImmunology, 2014, 3, e958952.	2.1	22
501	HYPOTHESIS: CYTOTOXIC LYMPHOCYTE GRANULE SERINE PROTEASES ACTIVATE TARGET CELL ENDONUCLEASES TO TRIGGER APOPTOSIS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 67-70.	0.9	21
502	Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research, 2011, 35, 14-21.	0.4	21
503	Both <scp>IFN</scp>â€Î³ and <scp>IL</scp>â€17 are required for the development of severe autoimmune gastritis. European Journal of Immunology, 2012, 42, 2574-2583.	1.6	21
504	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research, 2016, 76, 264-274.	0.4	21

#	Article	IF	Citations
505	Cytomegalovirus MHC class I homologues and natural killer cells: an overview. Microbes and Infection, 2000, 2, 521-532.	1.0	20
506	Flt-3L Expansion of Recipient CD8Î±+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD. Clinical Cancer Research, 2018, 24, 1604-1616.	3.2	20
507	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials, 2019, 20, 753.	0.7	20
508	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, 4, .	2.3	20
509	The mode of action of methotrexateâ€monoclonal antibody conjugates. Immunology and Cell Biology, 1987, 65, 189-200.	1.0	19
510	Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunology and Cell Biology, 2004, 82, 323-331.	1.0	19
511	NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function. Journal of Immunology, 2006, 177, 2575-2583.	0.4	19
512	Distinct receptor repertoire formation in mouse NK cell subsets regulated by MHC class I expression. Journal of Leukocyte Biology, 2008, 83, 106-111.	1.5	19
513	The Early Kinetics of Cytomegalovirus-Specific CD8⁺T-Cell Responses Are Not Affected by Antigen Load or the Absence of Perforin or Gamma Interferon. Journal of Virology, 2008, 82, 4931-4937.	1.5	19
514	ILâ€21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clinical and Translational Immunology, 2013, 2, e6.	1.7	19
515	ACCESSORY FUNCTION FOR NK1.1+ NATURAL KILLER CELLS PRODUCING INTERFERON-?? IN XENOSPECIFIC CYTOTOXIC T LYMPHOCYTE DIFFERENTIATION1. Transplantation, 1999, 68, 840-843.	0.5	19
516	Response to 'A cancer immunosurveillance controversy'. Nature Immunology, 2004, 5, 4-5.	7.0	18
517	Subsite specificities of granzyme M: a study of inhibitors and newly synthesized thiobenzyl ester substrates. Archives of Biochemistry and Biophysics, 2004, 422, 9-22.	1.4	18
518	Combination antibody-based cancer immunotherapy. Cancer Science, 2007, 98, 1297-1302.	1.7	18
519	Endogenous IL-21 Restricts CD8+ T Cell Expansion and Is not Required for Tumor Immunity. Journal of Immunology, 2009, 183, 7326-7336.	0.4	18
520	NK cell intrinsic regulation of MIP-1Î± by granzyme M. Cell Death and Disease, 2014, 5, e1115-e1115.	2.7	18
521	The atypical chemokine receptor CCXâ€CKR regulates metastasis of mammary carcinoma via an effect on EMT. Immunology and Cell Biology, 2014, 92, 815-824.	1.0	18
522	Type I <scp>NKT</scp>â€cellâ€mediated <scp>TNF</scp>â€Î± is a positive regulator of <scp>NLRP</scp>3 inflammasome priming. European Journal of Immunology, 2014, 44, 2111-2120.	1.6	18

#	Article	IF	Citations
523	NK Cell-Based Cancer Immunotherapy. Drug News and Perspectives, 2007, 20, 155.	1.9	18
524	Mechanisms of cytotoxicity used by human peripheral blood CD4+ and CD8+ T cell subsets. The role of granule exocytosis. Journal of Immunology, 1993, 151, 740-7.	0.4	18
525	Xenogeneic mouse antiâ€human NK cytotoxicity is mediated via perforin. Xenotransplantation, 1997, 4, 78-84.	1.6	17
526	Imatinib Mesylate â€" Uncovering a Fast Track to Adaptive Immunity. New England Journal of Medicine, 2006, 354, 2282-2284.	13.9	17
527	Homeostatic defects in interleukin 18â€deficient mice contribute to protection against the lethal effects of endotoxin. Immunology and Cell Biology, 2011, 89, 739-746.	1.0	17
528	A_{2A}blockade enhances anti-metastatic immune responses. OncoImmunology, 2013, 2, e26705.	2.1	17
529	Immunoediting of cancer metastasis by NK cells. Nature Cancer, 2020, 1, 670-671.	5.7	17
530	Purification and cloning of a novel serine protease, RNK-Tryp-2, from the granules of a rat NK cell leukemia. Journal of Immunology, 1994, 152, 2289-97.	0.4	17
531	Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity. Journal of Leukocyte Biology, 1995, 57, 88-93.	1.5	16
532	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. Journal of Immunology, 2014, 192, 5434-5441.	0.4	16
533	Rapid loss of group 1 innate lymphoid cells during blood stage Plasmodium infection. Clinical and Translational Immunology, 2018, 7, e1003.	1.7	16
534	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood, 1999, 93, 1075-1085.	0.6	16
535	NKG7 Is Required for Optimal Antitumor T-cell Immunity. Cancer Immunology Research, 2022, 10, 154-161.	1.6	16
536	Antigen Challenge Inhibits Thymic Emigration. Journal of Immunology, 2006, 176, 4553-4561.	0.4	15
537	Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16058.	1.8	15
538	PD1 functions by inhibiting CD28â€mediated coâ€stimulation. Clinical and Translational Immunology, 2017, 6, e138.	1.7	15
539	TGFÎ² shuts the door on T cells. British Journal of Cancer, 2018, 119, 1-3.	2.9	15
540	The gene encoding a human natural killer cell granule serine protease, Met-ase 1, maps to chromosome 19p13.3. Immunogenetics, 1994, 39, 294-5.	1.2	14

#	Article	IF	Citations
541	Adoptive transfer: The role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. Xenotransplantation, 1998, 5, 146-153.	1.6	14
542	Perforin-Dependent Cytolytic Responses in Î²2-Microglobulin-Deficient Mice. Cellular Immunology, 1999, 196, 51-59.	1.4	14
543	The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. OncoImmunology, 2012, 1, 377-379.	2.1	14
544	Granzyme M has a critical role in providing innate immune protection in ulcerative colitis. Cell Death and Disease, 2016, 7, e2302-e2302.	2.7	14
545	Multiple approaches to immunotherapy â€•the new pillar of cancer treatment. Immunology and Cell Biology, 2017, 95, 323-324.	1.0	14
546	Cancer Immunotherapy and the Nectin Family. Annual Review of Cancer Biology, 2021, 5, 203-219.	2.3	14
547	The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates. British Journal of Cancer, 1987, 55, 7-11.	2.9	13
548	Equivalent Death of P-Glycoprotein Expressing and Nonexpressing Cells Induced by the Protein Kinase C Inhibitor Staurosporine. Biochemical and Biophysical Research Communications, 2000, 276, 231-237.	1.0	13
549	A novel axis of innate immunity in cancer. Nature Immunology, 2010, 11, 981-982.	7.0	13
550	Antibody responses to glycolipidâ€borne carbohydrates require CD4⁺ T cells but not CD1 or NKT cells. Immunology and Cell Biology, 2011, 89, 502-510.	1.0	13
551	Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. OncoImmunology, 2012, 1, 1629-1631.	2.1	13
552	NKT cell adjuvants in therapeutic vaccines against hematological cancers. OncoImmunology, 2013, 2, e22615.	2.1	13
553	Innate myeloid cells in the tumor microenvironment. Current Opinion in Immunology, 2021, 69, 18-28.	2.4	13
554	Innate Tumor Immune Surveillance. Advances in Experimental Medicine and Biology, 2007, 590, 103-111.	0.8	13
555	Redirected Cytotoxic Effector Function. Journal of Biological Chemistry, 1996, 271, 21214-21220.	1.6	12
556	T Cells Gene-engineered with DAP12 Mediate Effector Function in an NKG2D-dependent and Major Histocompatibility Complex-independent Manner. Journal of Biological Chemistry, 2005, 280, 38235-38241.	1.6	12
557	A New Therapeutic Target for Leukemia Comes to the Surface. Cell, 2009, 138, 226-228.	13.5	12
558	The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. OncoImmunology, 2013, 2, e23036.	2.1	12

#	Article	IF	Citations
559	BRAF-targeted therapy and immune responses to melanoma. OncoImmunology, 2013, 2, e24462.	2.1	12
560	Dual mechanisms of lymphocytemediated cytotoxicity serve to control and deliver the immune response. BioEssays, 1995, 17, 891-898.	1.2	11
561	The natural killer cell serine protease gene Lmet1 maps to mouse chromosome 10. Immunogenetics, 1995, 41, 47-49.	1.2	11
562	Antitumor activities and onâ€target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer, 2011, 128, 2735-2747.	2.3	11
563	Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. OncoImmunology, 2012, 1, 1313-1322.	2.1	11
564	Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunology and Cell Biology, 2013, 91, 556-567.	1.0	11
565	Can Cancer Trigger Autoimmunity?. Science, 2014, 343, 147-148.	6.0	11
566	Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. OncoImmunology, 2016, 5, e1192740.	2.1	11
567	Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy. , 2020, 8, e001687.		11
568	Cloning and characterization of a novel NK cell-specific serine protease gene and its functional 5?-flanking sequences. Immunogenetics, 1995, 42, 101-11.	1.2	10
569	No requirement for TRAIL in intrathymic negative selection. International Immunology, 2008, 20, 267-276.	1.8	10
570	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23. Cancer Immunology Research, 2018, 6, 978-987.	1.6	10
571	EVIDENCE THAT AN ANTHRACYCLINE-ANTI-CD8 IMMUNOCONJUGATE, IDARUBICIN-ANTI-LY-2.1, PROLONGS HEART ALLOGRAFT SURVIVAL IN MICE. Transplantation, 1993, 55, 484-489.	0.5	8
572	IL-7 and the thymus dictate the NK cell 'labor market'. Nature Immunology, 2006, 7, 1134-1136.	7.0	8
573	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. OncoImmunology, 2014, 3, e963395.	2.1	8
574	Checkpoint Immunotherapy: Picking a Winner. Cancer Discovery, 2016, 6, 818-820.	7.7	8
575	Cloning and expression of the recombinant mouse natural killer cell granzyme Met-ase-1. Immunogenetics, 1996, 44, 340-350.	1.2	8
576	Use of the 5â€² -flanking region of the mouse perforin gene to express human FcÎ³ receptor I in cytotoxic T lymphocytes. Journal of Leukocyte Biology, 1994, 55, 514-522.	1.5	7

#	Article	IF	Citations
577	The peptide loop consisting of amino acids 139â€“157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse. Molecular Immunology, 1995, 32, 909-917.	1.0	7
578	Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative<i>gld/gld</i>mice. Journal of Leukocyte Biology, 2009, 85, 108-116.	1.5	7
579	Her 2 in 1. Cancer Cell, 2010, 18, 101-102.	7.7	7
580	Cancer Immunoediting. , 2013, , 85-99.		7
581	Physicochemical properties that control protein aggregation also determine whether a protein is retained or released from necrotic cells. Open Biology, 2016, 6, 160098.	1.5	7
582	Cancerâ€killing, decoyâ€resistant interleukinâ€18. Immunology and Cell Biology, 2020, 98, 434-436.	1.0	7
583	Systemic administration of ILâ€33 induces a population of circulating KLRG1 hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. Immunology and Cell Biology, 2021, 99, 65-83.	1.0	7
584	XENOSPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTE GENERATION. Transplantation, 1998, 65, 1278-1281.	0.5	7
585	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. Blood, 2008, 112, 3900-3900.	0.6	7
586	TNF contributes to the immunopathology of perforin/Fas ligand double deficiency. Immunology and Cell Biology, 2002, 80, 436-440.	1.0	6
587	Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after DNA immunization. Blood, 2004, 103, 3073-3075.	0.6	6
588	Contribution of IL-17â€“producing Î³Î´ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 869-869.	4.2	6
589	Targeting the IL-12/IL-23 axis. OncoImmunology, 2014, 3, e28964.	2.1	6
590	Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution. Journal of Virology, 2016, 90, 7497-7507.	1.5	6
591	ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome. Cancer Immunology Research, 2020, 8, 1085-1098.	1.6	6
592	Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicinâ€monoclonal antibody conjugates. Immunology and Cell Biology, 1993, 71, 167-179.	1.0	5
593	cDNA cloning of granzyme J. Immunogenetics, 1997, 45, 452-454.	1.2	5
594	Myeloid TGF-Î² Responsiveness Promotes Metastases. Cancer Discovery, 2013, 3, 846-848.	7.7	5

#	Article	IF	Citations
595	Natural Killer cell control ofBRAFV600Emutant melanoma during targeted therapy. OncoImmunology, 2015, 4, e998119.	2.1	5
596	The cellular uptake and cytotoxicity of chlorambucilâ€monoclonal autibody conjugates. Immunology and Cell Biology, 1987, 65, 315-321.	1.0	4
597	Differential regulation of interleukin-1 gene expression in human CD3âˆ’ large granular lymphocytes. Cellular Immunology, 1990, 131, 184-190.	1.4	4
598	Clarification of data used in three studies on MCA-induction of sarcoma in mice. Blood, 2008, 111, 4419-4419.	0.6	4
599	Response: dexamethasone dose alters expression of NK activating receptors in vivo. Blood, 2011, 118, 6466-6468.	0.6	4
600	Non-classical MHC Class I molecules regulating natural killer cell function. OncoImmunology, 2013, 2, e23336.	2.1	4
601	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. OncoImmunology, 2015, 4, e1038011.	2.1	4
602	Regulation of Immune Cell Functions through Nectin and Nectin-Like Receptors. , 2016, , 404-414.		4
603	IFN type III: <i>in vivo</i> NK cell response. Oncotarget, 2015, 6, 19960-19961.	0.8	4
604	Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model. Cancer Research, 1991, 51, 310-7.	0.4	4
605	Generation and cytotoxic profile of human peripheral blood CD4 ⁺ T lymphocytes. Immunology and Cell Biology, 1992, 70, 379-390.	1.0	3
606	Expression of human perforin in a mouse cytotoxic T lymphocyte cell line: evidence for perturbation of granule-mediated cytotoxicity. Journal of Leukocyte Biology, 1993, 54, 528-533.	1.5	3
607	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. Drug Development Research, 2001, 52, 549-557.	1.4	3
608	Purinergic Receptors: Novel Targets for Cancer Immunotherapy. , 2018, , 115-141.		3
609	Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells. , 2018, , 163-180.		3
610	Aberrant erythropoiesis fuels tumor growth. Cell Research, 2018, 28, 611-612.	5.7	3
611	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Journal of Clinical Investigation, 2013, 123, 3182-3182.	3.9	3
612	Potentiation of the in vitro cytotoxicity of chlorambucil by monoclonal antibodies. Journal of Immunology, 1986, 137, 3361-6.	0.4	3

#	Article	IF	Citations
613	IMMUNOSUPPRESSION OF GRAFT REJECTION WITH IDARUBICIN-MONOCLONAL ANTIBODY CONJUGATES BY ELIMINATION OF T CELL SUBSETS IN VIVO. Transplantation, 1988, 46, 126-131.	0.5	2
614	Immune surveillance of lymphoma in humans?. Blood, 2005, 105, 4159-4160.	0.6	2
615	Are We Really on the Right TRAIL?. Immunologic Research, 2005, 31, 161-164.	1.3	2
616	Innate Cancer Immunoediting. Journal of Investigative Dermatology, 2020, 140, 745-747.	0.3	2
617	Interleukin-21 and Cancer Therapy. , 2009, , 43-59.		2
618	Therapeutic Approaches Utilising NKT Cells. , 2012, , 111-128.		2
619	Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Cancer Research, 2012, 72, 526-526.	0.4	2
620	ROLE OF MONOCLONAL ANTIBODIES IN THE THERAPY OF SOLID TUMOURS. ANZ Journal of Surgery, 1988, 58, 843-849.	0.3	1
621	THE EFFECT OF IDARUBICIN MONOCLONAL ANTIBODY TREATMENT ON FIRST-SET REJECTION OF MURINE SKIN ALLOGRAFTS. Transplantation, 1989, 48, 77-79.	0.5	1
622	Cytotoxic lymphocyteâ€mediated immunotherapy. Australian and New Zealand Journal of Medicine, 1995, 25, 852-858.	0.5	1
623	Stress gets under your skin. Nature Immunology, 2008, 9, 119-120.	7.0	1
624	Immunotherapeutic strategies as adjuncts to local radiotherapy. Immunotherapy, 2012, 4, 129-131.	1.0	1
625	Liberating tumor immunity. Current Opinion in Immunology, 2012, 24, 204-206.	2.4	1
626	Natural Killers out of Thin Air. Immunity, 2020, 52, 895-897.	6.6	1
627	Discovery of an Innate Cancer Resistance Gene?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 186-189.	3.4	1
628	Promoting Regulation Via the Inhibition of DNAM-1 After Transplantation. Blood, 2012, 120, 338-338.	0.6	1
629	Molecular Mechanisms of Lymphocyte Cytotoxicity. , 1993, , 223-234.		1
630	The question begs â€" what is the role of P-glycoprotein in normal physiology?. Drug Resistance Updates, 1998, 1, 340-342.	6.5	0

#	Article	IF	Citations
631	P-glycoprotein as a General Antiapoptotic Protein. , 2002, , 433-441.		0
632	Letter to the Editor. Immunologic Research, 2004, 30, 255-256.	1.3	0
633	Antibody responses to glycolipidâ€borne carbohydrates require CD4⁺ T cells but not CD1 or NKT cells. Immunology and Cell Biology, 2011, 89, 574-574.	1.0	0
634	Death receptor-induced apoptosis signalling - essential guardian against autoimmune disease. Arthritis Research and Therapy, 2012, 14, .	1.6	0
635	Granzyme M. , 2013, , 2728-2731.		0
636	Cytokine-driven role of Srebps in killer cell metabolism. Nature Immunology, 2017, 18, 1183-1184.	7.0	0
637	EVIDENCE FOR THE EXISTENCE OF CANCER IMMUNOSURVEILLANCE. Annals of Cancer Research and Therapy, 2004, 12, 9-32.	0.1	0
638	Adoptive Transfer of Chimeric Fc?RI Gene-Modified Human T Cells for Cancer Immunotherapy. Human Gene Therapy, 2006, .	1.4	0
639	Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of G-CSF after Bone Marrow Transplantation. Blood, 2008, 112, 3499-3499.	0.6	0
640	Anti-Tumor Activity of Genetically Redirected T Cells Against Orthotopic Kidney Cancer in Mice~!2010-01-06~!2010-03-24~!2010-05-13~!. The Open Gene Therapy Journal, 2010, 3, 1-7.	1.2	0
641	Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewisy Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,. Blood, 2011, 118, 4180-4180.	0.6	0
642	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.. Journal of Clinical Oncology, 2018, 36, e21001-e21001.	0.8	0
643	Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure. Blood, 2018, 132, 2031-2031.	0.6	0
644	Oncogenic-Drivers Dictate Immune Responses to Control Disease Progression in Acute Myeloid Leukaemia. Blood, 2018, 132, 904-904.	0.6	0
645	Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. Journal of Clinical Oncology, 2019, 37, TPS129-TPS129.	0.8	0
646	Experimental Models of Cytokines and Cancer Prevention. , 2007, , 211-230.		0
647	The Immune System and Progression from Precursor Condition to Active Myeloma. Blood, 2020, 136, SCI5-SCI5.	0.6	0
648	Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer. Targeted Diagnosis and Therapy, 1988, 1, 123-56.	0.1	0

#	Article	IF	Citations
649	Abstract 359: CD4+ Natural Killer T Cells Promote Atherosclerosis via Cytotoxic Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0